Screening and comorbidity of clinical levels of fear of cancer recurrence

Simard, Sébastien; Savard, Josée

doi:10.1007/s11764-015-0424-4

Cited by 242 publications

(329 citation statements)

References 41 publications

Supporting

Mentioning

293

Contrasting

Unclassified

Order By: Relevance

“…A score of !14 is optimal for differentiating between high and low FCR in breast cancer survivors [15]. To determine the optimal cutoff point, and to evaluate the accuracy of the CWS in identifying PCa survivors with low versus high FCR, a receiver operating characteristic (ROC) analysis with the eight-item CWS and the Fear of Cancer Recurrence Inventory -Severity subscale (FCRI-Severity) was performed (using the clinical cutoff score of !16 to indicate high FCR) [12]. The area under the curve was 0.93 (p < 0.001; 95% CI 0.89-0.96) (Appendix 1, available online at http://www.informahealthcare.com), which represents a good level of discrimination.…”

Section: Fear Of Cancer Recurrence: Severitymentioning

confidence: 96%

“…The 42-item Fear of Cancer Recurrence Inventory (FCRI) is a psychometrically sound questionnaire used to assess multidimensional aspects of FCR [2,12]. Seven subscales were used: Triggers (8-items), Severity (9-items), Psychological Distress (4-items), Functioning Impairments (6-items), Insight (3-items), Reassurance seeking (3-items) and Coping (9-items).…”

Section: Fear Of Cancer Recurrence: Multidimensional Aspectsmentioning

confidence: 99%

“…FCR in PCa survivors has been described in some studies [6,[8][9][10][11][12], but only one study has reported the prevalence of high FCR using a validated cutoff score [12]. While mean levels of FCR were found to be lower in PCa survivors compared to those with breast, colorectal or lung cancer [2,6]; the prevalence of high FCR was higher in PCa survivors (32%, n ¼ 23) than colorectal cancer survivors (24%, n ¼ 10), but lower than in breast cancer survivors (40%, n ¼ 23) (significance testing was not conducted).…”

mentioning

confidence: 94%

See 2 more Smart Citations

Fear of cancer recurrence in prostate cancer survivors

et al. 2016

View full text Add to dashboard Cite

Background High fear of cancer recurrence (FCR) is an understudied topic in prostate cancer (PCa) survivors. This study aimed to detect the prevalence, consequences and characteristics associated with high FCR in PCa survivors. Material and methods This cross-sectional study included patients diagnosed with localized PCa and treated with curative radical prostatectomy between 1992 and 2012. We administered the Cancer Worry Scale (CWS) to assess FCR severity (primary outcome measure). Secondary outcomes included distress, quality of life (QOL), post-traumatic symptoms, and multidimensional aspects of FCR. v

show abstract

Section: Fear Of Cancer Recurrence: Severitymentioning

confidence: 96%

Section: Fear Of Cancer Recurrence: Multidimensional Aspectsmentioning

confidence: 99%

mentioning

confidence: 94%

See 1 more Smart Citation

Fear of cancer recurrence in prostate cancer survivors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The interpretation of these themes intended, first, to describe and specify the needs of the target population and, second, to describe the Fillion et al (2011) N.B. : SUNS = Survivor Unmet Needs Survey (Campbell et al, 2011); FCRI = Fear of Cancer Recurrence Inventory (Simard & Savard, 2015); HeiQ = Health Education Impact Questionnaire (Osborne et al, 2007).…”

Section: Data Analysesmentioning

confidence: 99%

“…Emotional and psychological needs are common during this phase, more specifically, concerns about recurrence, about long-lasting and late side effects, and about the possibility of a reduced life expectancy (Dahl et al, 2013;Simard et al, 2013). Some studies suggest that survivors with high levels of fear of recurrence are more likely to develop anxiety problems (Simard & Savard, 2015). There is a correspondence between the expression of FCR by WEC and the feeling of anxiety frequently observed in the year following the end of the initial treatment and often associated with a fear of the disease recurring (Harrington et al, 2010;Salani, 2013).…”

Section: Taking Into Account the Needs Of Wecmentioning

confidence: 99%

Development and validation of an individualized survivorship care plan (ISCP) for women with endometrial cancer during the transition of the end of active treatment to the cancer survivorship

Hébert

Fillion

2017

CONJ

View full text Add to dashboard Cite

show abstract

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma

et al. 2018

View full text Add to dashboard Cite

IMPORTANCE The diagnosis of a life-threatening disease like melanoma can affect all aspects of a person's life, including health-related quality of life (HRQOL) and psychological aspects of melanoma such as fear of cancer recurrence (FCR). Economic evaluations of psychological interventions require preference-based (utility) instruments that are sensitive to changes in well-being and HRQOL; however, very few studies have evaluated the sensitivity of these instruments when used for people with melanoma. OBJECTIVE To compare utility scores from the multiple-attribute instrument Assessment of Quality of Life-8-Dimension Scale (AQoL-8D) with the mapped utility scores of the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) and to investigate the sensitivity of both instruments in identifying the influence of FCR on HRQOL. DESIGN, SETTING, AND PARTICIPANTS This assessment of data from a randomized clinical trial of a psychoeducational intervention to reduce FCR, conducted at 3 high-risk melanoma clinics in Australia, evaluated 164 patients with early-stage melanoma and a high risk of developing a second primary melanoma. MAIN OUTCOMES AND MEASURES The FACT-M and AQoL-8D were used to assess HRQOL and FCR among the study participants. Concurrent validity was assessed by comparing the total and subdomain scores of the 2 instruments, and the strength of associations was assessed using Pearson correlation coefficient. Convergent validity was assessed by comparing participants' HRQOL, demographic, and clinical characteristics using the χ 2 test and F statistic. Both the FACT-M and AQoL-8D utilities were regressed on FCR Inventory (FCRI) severity scores to estimate the effect of elevated FCR on HRQOL. RESULTS A total of 164 participants completed the baseline questionnaires, but only 163 met all inclusion criteria and underwent the full analysis: 72 were women; 91 were men; and mean (SD) age was 58.2 (12.1) years. Both the AQoL-8D and FACT-M instruments showed good concurrent validity and could differentiate between relevant subgroups including level of FCRI severity. The AQoL-8D and FACT-M utilities were strongly correlated (r 2 = 0.57). Respondents had a mean (SD) AQoL-8D utility of 0.77 (0.2), and a mean (SD) FACT-M utility score of 0.76 (0.07). High levels of FCRI severity were associated with a decrease in utility of 0.12 (95% CI, −0.19 to −0.05) as measured by AQoL-8D, and a decrease of 0.03 (95% CI, −0.05 to −0.01) as measured by the FACT-M. CONCLUSIONS AND RELEVANCE For economic evaluations of psychological interventions in melanoma, the AQoL-8D and FACT-M are valid measures of utility; however, the AQoL-8D demonstrates greater sensitivity to FCRI severity. Our results suggest a significant association between FCR and HRQOL.

show abstract

Screening and comorbidity of clinical levels of fear of cancer recurrence

Abstract: The FCRI-SF allows rapid and effective screening of clinical levels of FCR, a condition associated with significant psychiatric comorbidity.

Cited by 242 publications

References 41 publications

Fear of cancer recurrence in prostate cancer survivors

Fear of cancer recurrence in prostate cancer survivors

Development and validation of an individualized survivorship care plan (ISCP) for women with endometrial cancer during the transition of the end of active treatment to the cancer survivorship

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma

Contact Info

Product

Resources

About